1. Home
  2. BCAB vs OESX Comparison

BCAB vs OESX Comparison

Compare BCAB & OESX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • OESX
  • Stock Information
  • Founded
  • BCAB 2007
  • OESX 1996
  • Country
  • BCAB United States
  • OESX United States
  • Employees
  • BCAB N/A
  • OESX N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • OESX Building Products
  • Sector
  • BCAB Health Care
  • OESX Consumer Discretionary
  • Exchange
  • BCAB Nasdaq
  • OESX Nasdaq
  • Market Cap
  • BCAB 40.5M
  • OESX 34.1M
  • IPO Year
  • BCAB 2020
  • OESX 2007
  • Fundamental
  • Price
  • BCAB $0.78
  • OESX $14.00
  • Analyst Decision
  • BCAB Hold
  • OESX Strong Buy
  • Analyst Count
  • BCAB 3
  • OESX 2
  • Target Price
  • BCAB $1.00
  • OESX $17.50
  • AVG Volume (30 Days)
  • BCAB 1.2M
  • OESX 35.4K
  • Earning Date
  • BCAB 11-13-2025
  • OESX 11-05-2025
  • Dividend Yield
  • BCAB N/A
  • OESX N/A
  • EPS Growth
  • BCAB N/A
  • OESX N/A
  • EPS
  • BCAB N/A
  • OESX N/A
  • Revenue
  • BCAB N/A
  • OESX $79,947,000.00
  • Revenue This Year
  • BCAB N/A
  • OESX $6.70
  • Revenue Next Year
  • BCAB N/A
  • OESX $13.43
  • P/E Ratio
  • BCAB N/A
  • OESX N/A
  • Revenue Growth
  • BCAB N/A
  • OESX N/A
  • 52 Week Low
  • BCAB $0.24
  • OESX $5.50
  • 52 Week High
  • BCAB $2.05
  • OESX $14.24
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.58
  • OESX 75.23
  • Support Level
  • BCAB $0.62
  • OESX $11.42
  • Resistance Level
  • BCAB $0.73
  • OESX $13.65
  • Average True Range (ATR)
  • BCAB 0.09
  • OESX 0.99
  • MACD
  • BCAB 0.00
  • OESX 0.43
  • Stochastic Oscillator
  • BCAB 47.44
  • OESX 98.53

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About OESX Orion Energy Systems Inc.

Orion Energy Systems Inc is engaged in light-emitting diode lighting systems, wireless Internet of Things-enabled control solutions, project engineering, energy project management design, maintenance services, and turnkey electric vehicle charging stations and related installation services to commercial and industrial businesses, and federal and local governments, predominantly in North America. The group has three segments: the Orion lighting segment, the Orion maintenance segment, and the Orion electric vehicle charging segment. It generates the majority of its revenue from the Orion lighting segment, which develops and sells lighting products and provides construction and engineering services for Orion's commercial lighting and energy management systems.

Share on Social Networks: